17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Galectin-3 is an endogenous lectin that binds glycan epitopes of cell membrane and some extracellular glycoproteins such as integrins and laminin. Galectin-3 is involved in several biological activities including regulation of cellular cycle, modulation of adhesion and tumor progression and metastasis. 90K/Mac-2BP glycoprotein is also a serum galectin-3 ligand. 90K is able to modulate the immune reaction against tumors and viruses and its level increases in sera of several neoplastic diseases. In our study, we have evaluated levels of both glycoproteins in sera of non metastatic colon cancer patients. Interestingly, galectin-3 ranged higher in cancer patients than in controls (p<0.0001), particularly in more differentiated tumors (p<0.04). Moreover, 90K mean values ranged higher in right-side than in left-side colon cancer. In conclusion, serum galectin3 might represent a useful biomarker to evaluate colon cancer transformation and, together with its ligand 90K, could contribute to the characterization of colon cancer.

          Related collections

          Author and article information

          Journal
          Immunopharmacol Immunotoxicol
          Immunopharmacology and immunotoxicology
          Informa UK Limited
          1532-2513
          0892-3973
          Mar 2010
          : 32
          : 1
          Affiliations
          [1 ] Clinical Pathology, University of Bari, Bari, Italy. mina.iacovazzi@irccsdebellis.it
          Article
          10.1080/08923970902936880
          19686089
          75efe65b-b3e8-4a34-ad94-13a5c6fbf312
          History

          Comments

          Comment on this article